Cargando…

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ

Although ductal carcinoma in situ (DCIS) is a non-obligate precursor to ipsilateral invasive breast cancer (iIBC), most DCIS lesions remain indolent. Hence, overdiagnosis and overtreatment of DCIS is a major concern. There is an urgent need for prognostic markers that can distinguish harmless from p...

Descripción completa

Detalles Bibliográficos
Autores principales: Almekinders, Mathilde M. M., Schaapveld, Michael, Thijssen, Bram, Visser, Lindy L., Bismeijer, Tycho, Sanders, Joyce, Isnaldi, Edoardo, Hofland, Ingrid, Mertz, Marjolijn, Wessels, Lodewyk F. A., Broeks, Annegien, Hooijberg, Erik, Zwart, Wilbert, Lips, Esther H., Desmedt, Christine, Wesseling, Jelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985299/
https://www.ncbi.nlm.nih.gov/pubmed/33753731
http://dx.doi.org/10.1038/s41523-021-00232-w
_version_ 1783668215984947200
author Almekinders, Mathilde M. M.
Schaapveld, Michael
Thijssen, Bram
Visser, Lindy L.
Bismeijer, Tycho
Sanders, Joyce
Isnaldi, Edoardo
Hofland, Ingrid
Mertz, Marjolijn
Wessels, Lodewyk F. A.
Broeks, Annegien
Hooijberg, Erik
Zwart, Wilbert
Lips, Esther H.
Desmedt, Christine
Wesseling, Jelle
author_facet Almekinders, Mathilde M. M.
Schaapveld, Michael
Thijssen, Bram
Visser, Lindy L.
Bismeijer, Tycho
Sanders, Joyce
Isnaldi, Edoardo
Hofland, Ingrid
Mertz, Marjolijn
Wessels, Lodewyk F. A.
Broeks, Annegien
Hooijberg, Erik
Zwart, Wilbert
Lips, Esther H.
Desmedt, Christine
Wesseling, Jelle
author_sort Almekinders, Mathilde M. M.
collection PubMed
description Although ductal carcinoma in situ (DCIS) is a non-obligate precursor to ipsilateral invasive breast cancer (iIBC), most DCIS lesions remain indolent. Hence, overdiagnosis and overtreatment of DCIS is a major concern. There is an urgent need for prognostic markers that can distinguish harmless from potentially hazardous DCIS. We hypothesised that features of the breast adipose tissue may be associated with risk of subsequent iIBC. We performed a case–control study nested in a population-based DCIS cohort, consisting of 2658 women diagnosed with primary DCIS between 1989 and 2005, uniformly treated with breast conserving surgery (BCS) alone. We assessed breast adipose features with digital pathology (HALO(®), Indica Labs) and related these to iIBC risk in 108 women that developed subsequent iIBC (cases) and 168 women who did not (controls) by conditional logistic regression, accounting for clinicopathological and immunohistochemistry variables. Large breast adipocyte size was significantly associated with iIBC risk (odds ratio (OR) 2.75, 95% confidence interval (95% CI) = 1.25–6.05). High cyclooxygenase (COX)-2 protein expression in the DCIS cells was also associated with subsequent iIBC (OR 3.70 (95% CI = 1.59–8.64). DCIS with both high COX-2 expression and large breast adipocytes was associated with a 12-fold higher risk (OR 12.0, 95% CI = 3.10–46.3, P < 0.001) for subsequent iIBC compared with women with smaller adipocyte size and low COX-2 expression. Large breast adipocytes combined with high COX-2 expression in DCIS is associated with a high risk of subsequent iIBC. Besides COX-2, adipocyte size has the potential to improve clinical management in patients diagnosed with primary DCIS.
format Online
Article
Text
id pubmed-7985299
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79852992021-04-16 Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ Almekinders, Mathilde M. M. Schaapveld, Michael Thijssen, Bram Visser, Lindy L. Bismeijer, Tycho Sanders, Joyce Isnaldi, Edoardo Hofland, Ingrid Mertz, Marjolijn Wessels, Lodewyk F. A. Broeks, Annegien Hooijberg, Erik Zwart, Wilbert Lips, Esther H. Desmedt, Christine Wesseling, Jelle NPJ Breast Cancer Article Although ductal carcinoma in situ (DCIS) is a non-obligate precursor to ipsilateral invasive breast cancer (iIBC), most DCIS lesions remain indolent. Hence, overdiagnosis and overtreatment of DCIS is a major concern. There is an urgent need for prognostic markers that can distinguish harmless from potentially hazardous DCIS. We hypothesised that features of the breast adipose tissue may be associated with risk of subsequent iIBC. We performed a case–control study nested in a population-based DCIS cohort, consisting of 2658 women diagnosed with primary DCIS between 1989 and 2005, uniformly treated with breast conserving surgery (BCS) alone. We assessed breast adipose features with digital pathology (HALO(®), Indica Labs) and related these to iIBC risk in 108 women that developed subsequent iIBC (cases) and 168 women who did not (controls) by conditional logistic regression, accounting for clinicopathological and immunohistochemistry variables. Large breast adipocyte size was significantly associated with iIBC risk (odds ratio (OR) 2.75, 95% confidence interval (95% CI) = 1.25–6.05). High cyclooxygenase (COX)-2 protein expression in the DCIS cells was also associated with subsequent iIBC (OR 3.70 (95% CI = 1.59–8.64). DCIS with both high COX-2 expression and large breast adipocytes was associated with a 12-fold higher risk (OR 12.0, 95% CI = 3.10–46.3, P < 0.001) for subsequent iIBC compared with women with smaller adipocyte size and low COX-2 expression. Large breast adipocytes combined with high COX-2 expression in DCIS is associated with a high risk of subsequent iIBC. Besides COX-2, adipocyte size has the potential to improve clinical management in patients diagnosed with primary DCIS. Nature Publishing Group UK 2021-03-22 /pmc/articles/PMC7985299/ /pubmed/33753731 http://dx.doi.org/10.1038/s41523-021-00232-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Almekinders, Mathilde M. M.
Schaapveld, Michael
Thijssen, Bram
Visser, Lindy L.
Bismeijer, Tycho
Sanders, Joyce
Isnaldi, Edoardo
Hofland, Ingrid
Mertz, Marjolijn
Wessels, Lodewyk F. A.
Broeks, Annegien
Hooijberg, Erik
Zwart, Wilbert
Lips, Esther H.
Desmedt, Christine
Wesseling, Jelle
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
title Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
title_full Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
title_fullStr Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
title_full_unstemmed Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
title_short Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
title_sort breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985299/
https://www.ncbi.nlm.nih.gov/pubmed/33753731
http://dx.doi.org/10.1038/s41523-021-00232-w
work_keys_str_mv AT almekindersmathildemm breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT schaapveldmichael breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT thijssenbram breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT visserlindyl breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT bismeijertycho breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT sandersjoyce breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT isnaldiedoardo breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT hoflandingrid breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT mertzmarjolijn breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT wesselslodewykfa breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT broeksannegien breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT hooijbergerik breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT zwartwilbert breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT lipsestherh breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT desmedtchristine breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu
AT wesselingjelle breastadipocytesizeassociateswithipsilateralinvasivebreastcancerriskafterductalcarcinomainsitu